科济药业-B(02171)：CT0596已获得国家药监局的IND批准用于治疗复发/难治的多发性骨髓瘤(R/R MM)患者

智通财经08-04

智通财经APP讯，科济药业-B(02171)发布公告，CT0596，一种靶向BCMA的通用型CAR-T细胞产品，已获得国家药品监督管理局的IND批准，用于治疗复发/难治的多发性骨髓瘤(R/R MM)患者。CT0596的IIT研究结果已在2026年欧洲血液学协会(EHA)年会上进行壁报展示。

CT0596是一款靶向BCMA的通用型CAR-T细胞疗法，基于科济药业自主研发的 THANK-u Plus™平台开发，目前正在R/R MM或浆细胞白血病(PCL)中开展IIT进行评估。CT0596显示出初步良好的安全性及令人鼓舞的疗效信号。本公司还计划在其他浆细胞肿瘤以及自身反应性浆细胞驱动的自身免疫性疾病中进一步探索。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohunote.com/m/news/2656588739?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-08-04 08:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2656588739","market":"fut","top_or_hot":-1,"title":"科济药业-B(02171)：CT0596已获得国家药监局的IND批准用于治疗复发/难治的多发性骨髓瘤(R/R MM)患者","media":"智通财经","content":"<html><body><p>智通财经APP讯，<a href=\"https://laohu8.com/S/02171\">科济药业-B</a>(02171)发布公告，CT0596，一种靶向BCMA的通用型CAR-T细胞产品，已获得国家药品监督管理局的IND批准，用于治疗复发/难治的多发性骨髓瘤(R/R MM)患者。CT0596的IIT研究结果已在2026年欧洲血液学协会(EHA)年会上进行壁报展示。</p><p>CT0596是一款靶向BCMA的通用型CAR-T细胞疗法，基于科济药业自主研发的 THANK-u Plus™平台开发，目前正在R/R MM或浆细胞白血病(PCL)中开展IIT进行评估。CT0596显示出初步良好的安全性及令人鼓舞的疗效信号。本公司还计划在其他浆细胞肿瘤以及自身反应性浆细胞驱动的自身免疫性疾病中进一步探索。</p></body></html>","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>科济药业-B(02171)：CT0596已获得国家药监局的IND批准用于治疗复发/难治的多发性骨髓瘤(R/R MM)患者</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n科济药业-B(02171)：CT0596已获得国家药监局的IND批准用于治疗复发/难治的多发性骨髓瘤(R/R MM)患者\n</h2>\n\n<h4 class=\"meta\">\n\n</h4>\n\n</header>\n<article>\n<html><body><p>智通财经APP讯，<a href=\"https://laohu8.com/S/02171\">科济药业-B</a>(02171)发布公告，CT0596，一种靶向BCMA的通用型CAR-T细胞产品，已获得国家药品监督管理局的IND批准，用于治疗复发/难治的多发性骨髓瘤(R/R MM)患者。CT0596的IIT研究结果已在2026年欧洲血液学协会(EHA)年会上进行壁报展示。</p><p>CT0596是一款靶向BCMA的通用型CAR-T细胞疗法，基于科济药业自主研发的 THANK-u Plus™平台开发，目前正在R/R MM或浆细胞白血病(PCL)中开展IIT进行评估。CT0596显示出初步良好的安全性及令人鼓舞的疗效信号。本公司还计划在其他浆细胞肿瘤以及自身反应性浆细胞驱动的自身免疫性疾病中进一步探索。</p></body></html>\n\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"http://www.zhitongcaijing.com/content/detail/1475535.html\">智通财经</a> </p>\n\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n</div>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1475535.html","article_id":"2656588739","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2656588739","pubTimestamp":1785802294,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，科济药业-B 发布公告，CT0596，一种靶向BCMA的通用型CAR-T细胞产品，已获得国家药品监督管理局的IND批准，用于治疗复发/难治的多发性骨髓瘤患者。CT0596的IIT研究结果已在2026年欧洲血液学协会年会上进行壁报展示。CT0596是一款靶向BCMA的通用型CAR-T细胞疗法，基于科济药业自主研发的 THANK-u Plus平台开发，目前正在R/R MM或浆细胞白血病中开展IIT进行评估。CT0596显示出初步良好的安全性及令人鼓舞的疗效信号。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1161":"生物科技","BK1574":"生物医药B类股","BK1587":"次新股","BK1585":"昨日强势股","02171":"科济药业-B","IND":"Xtrackers Nifty 500 India ETF"},"translate_title":"Keji Pharmaceutical-B (02171): CT0596 has been approved by the IND of the NMPA for the treatment of patients with relapsed/refractory multiple myeloma (R/R MM)","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02171":1.5,"IND":1.5},"content_text":"智通财经APP讯，科济药业-B(02171)发布公告，CT0596，一种靶向BCMA的通用型CAR-T细胞产品，已获得国家药品监督管理局的IND批准，用于治疗复发/难治的多发性骨髓瘤(R/R MM)患者。CT0596的IIT研究结果已在2026年欧洲血液学协会(EHA)年会上进行壁报展示。CT0596是一款靶向BCMA的通用型CAR-T细胞疗法，基于科济药业自主研发的 THANK-u Plus™平台开发，目前正在R/R MM或浆细胞白血病(PCL)中开展IIT进行评估。CT0596显示出初步良好的安全性及令人鼓舞的疗效信号。本公司还计划在其他浆细胞肿瘤以及自身反应性浆细胞驱动的自身免疫性疾病中进一步探索。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2656588739","isCrawlerRequest":true}